HIV-1 drug resistance in adults with HIV/TB on rifampicin receiving bictegravir or dolutegravir in South Africa: The INSIGHT trial
Open Forum Infectious Diseases · 13.11.2026
DOI: 10.1093/ofid/ofag741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Benjamin Chimukangara und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Emergence of HIV-1 drug resistance (HIVDR) during bictegravir/emtricitabine/tenofovir alafenamide treatment with rifampicin-based tuberculosis (TB) treatment has not been studied.
Methods
We analysed plasma samples from INSIGHT (NCT04734652), a phase 2b, open-label, non-comparative, randomised trial in adults with HIV/TB (CD4 ≥50 cells/mm3, ART-naïve or off ART for ≥3 months) receiving twice-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC-arm) or twice-daily dolutegravir with once-daily tenofovir disoproxil fumarate and lamivudine (DTG-arm) during TB treatment in Durban, South Africa. This resistance sub-study used remnant samples to assess emergent HIVDR outcomes. Genotypic testing (Illumina MiSeq) was performed on baseline samples and longitudinally on samples with HIV-1 viral loads ≥50 RNA copies/mL at weeks 24, 40, and 48.
Results
Median baseline HIV-1 RNA was 4·89 log10 copies/mL (IQR 4·40–5·60) and median CD4 count was 151 cells/mm3 (IQR 99–296). HIV-1 pol genotypes were obtained for 113 participants (74/80 BIC-arm; 39/42 DTG-arm). At baseline, 36/113 (32%) participants had HIVDR mutations at ≥20% frequency, most commonly K103N (61%, 22/36). No major integrase strand transfer inhibitor (INSTI) mutations were detected at baseline, however, 11% (4/36) harbored INSTI accessory mutations (L74M, Q95K, T97A). From week 24 onwards, eight participants (7·1%) with viral non-suppression (≥50 RNA copies/mL) had follow-up genotypes available (5/8 BIC-arm; 3/8 DTG-arm). No emergent INSTI mutations were observed, and one participant (DTG-arm) developed emergent M184V/I mutations.
Conclusions
In this trial setting, twice-daily bictegravir/emtricitabine/tenofovir alafenamide during rifampicin treatment maintained high rates of viral suppression with no emergent INSTI resistance through 48 weeks. These findings support bictegravir as an alternative to dolutegravir among adults with HIV/TB and CD4 counts ≥50 cells/mm3 receiving rifampicin-based treatment.
Zitieren
APA
Chimukangara, B., Li, J. Z., Mbhele, N., Choga, W. T., Amusa, L. B., Osuala, E. C., Perumal, R., Naidoo, K., Dooley, K. E., & Naidoo, A. (2026). HIV-1 drug resistance in adults with HIV/TB on rifampicin receiving bictegravir or dolutegravir in South Africa: The INSIGHT trial. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag741
Vancouver
Chimukangara B, Li JZ, Mbhele N, Choga WT, Amusa LB, Osuala EC, et al. HIV-1 drug resistance in adults with HIV/TB on rifampicin receiving bictegravir or dolutegravir in South Africa: The INSIGHT trial. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag741
BibTeX
@article{Chimukangara2026,
author = {Chimukangara, Benjamin and Li, Jonathan Z and Mbhele, Nokuzola and Choga, Wonderful T and Amusa, Lateef Babatunde and Osuala, Emmanuella Chinonso and Perumal, Rubeshan and Naidoo, Kogieleum and Dooley, Kelly E and Naidoo, Anushka},
title = {HIV-1 drug resistance in adults with HIV/TB on rifampicin receiving bictegravir or dolutegravir in South Africa: The INSIGHT trial},
journal = {Open Forum Infectious Diseases},
year = {2026},
doi = {10.1093/ofid/ofag741}
}
EUVIMED